A Phase II Study of VP-103 in Subjects with Plantar Warts
Latest Information Update: 29 May 2020
At a glance
- Drugs Cantharidin (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors Verrica Pharmaceuticals
- 27 May 2020 According to a Verrica Pharmaceuticals media release, the company is conducting necessary preclinical activities for VP-103 and, in light of the COVID-19 pandemic, intends to launch this Phase 2 clinical trial in subjects with plantar warts when conditions are appropriate.
- 31 Mar 2020 New trial record
- 13 Mar 2020 According to a Verrica Pharmaceuticals media release, the company intends to start this trial at least through the second quarter of 2021.